FindTrial
Sign In

Effect of zinc in treatment of nephrotic syndrome

Zinc therapy in childhood nephrosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032706
Enrollment
30
Registered
2021-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes

Interventions

Intervention1: zinc: 20mg (1ml) once daily orally for three months Control Intervention1: multivitamin drops: 1ml once daily orally for three months

Sponsors

MLNMedical college Allahabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. normal kidney fuction 2.first episode of nephrotic syndrome or relapse of nephrotic syndrome 3.steroid sensitive nephrotic syndrome

Exclusion criteria

Exclusion criteria: 1. clinical evidence of malnutrition or systemic disease 2. those on zinc supplementation 3.congenital nephrotic syndrome or infantile nephrotic syndrome

Design outcomes

Primary

MeasureTime frame
1. time to remission between test and control groups 2.changes in zinc levels during initial episode/relapse in test and control groupsTimepoint: when child will attain remission—

Secondary

MeasureTime frame
1. frequency of relapses in 6 months. 2. mean time to next relapse 3.adverse effects of therapyTimepoint: 6 months—

Countries

India

Contacts

Public ContactPreeti Singh Solanki

M.L.N.Medical college

anubhashrivastava@rediffmail.com9236804326

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026